Navigation Links
zuChem Receives Two Polyol Patents

Chicago, IL (PRWEB) June 17, 2013

zuChem Inc., a leading producer of unique carbohydrates for human health and nutrition, announced today that the United States Patent and Trademark office has recently issued 2 patents - US 8,367,346 entitled “Methods for Production of Xylitol in Microorganisms,” and US 8,338,147 entitled "Process for producing D-Mannitol." These two patents expand zuChem's technology portfolio for the fermentative production of natural food sweetener products from abundant, renewable feedstocks.

The xylitol technology was developed by zuChem in collaboration with the U.S. Department of Agriculture, Agricultural Research Service’s National Center for Agricultural Utilization Research and the Biotechnology Research and Development Corporation (BRDC) under a Cooperative Research and Development Agreement. zuChem is the exclusive licensee of this patent under its relationship with the BRDC, to whom this patent is assigned. The mannitol technology was acquired from Hydrios Biotechnology Ltd. of Helsinki, Finland as part of a portfolio of patents developed by Hydrios and the Laboratory of Bioprocess Engineering at Helsinki University of Technology. This technology is now an important component of zuChem’s fermentative mannitol process, which has been approved by the FDA as a safe and effective method for the production of mannitol.

Xylitol and mannitol belong to a class of specialty sweeteners called polyols, and have traditionally been produced from by chemical hydrogenation. The demand for these sweeteners is on the rise because of their unique health properties and growing demand in products such as gum, candy, beverages, diabetic foods and other sugar-free confectionery products. zuChem’s processes are natural fermentative alternatives to the chemical process and utilize readily available biomass as feedstocks.

“We are very pleased by this addition to our intellectual property portfolio on novel biosynthetic production processes of both xylitol and mannitol,” David Demirjian, Ph.D., President and CEO, zuChem. “Our xylitol process is now in scale-up with our first commercial manufacturing partner and we hope to have product on the market in 2014.” Dr. Demirjian is slated to give a presentation of the xylitol process at the World Congress on Industrial Biotechnology on June 17th in Montreal, Canada.

About zuChem, Inc.

zuChem focuses on commercializing innovative manufacturing processes for unique specialized carbohydrates for the food, fine chemicals and pharmaceutical intermediates industries. These specialized carbohydrates are key components of many drugs and drug candidates as well as many specialty food ingredients. The company is headquartered in Chicago, IL, with research operations in Peoria, IL.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. UCSB professor receives award for graphene electronics research
2. Watsons Generic Yaz(R) Receives FDA Approval
3. Quanterix Receives Funding From the Department of Homeland Security to Develop Test for Botulinum Toxin
4. Life Technologies Ion Personal Genome Machine Receives San Diegos CONNECT Most Innovative New Product Award
5. MacroGenics Receives Milestone Payment as Part of Its Global DART™ Alliance with Boehringer Ingelheim
6. Intimate Bridge 2 Conception, Inc. Receives $4.3M
7. Pacific Meso Center Receives Generous Donation to First Free-Standing Mesothelioma Research Laboratory in Los Angeles
8. BioNeutral Group Receives $400,000 in Equity Financing
9. Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
10. Arcion Receives Notice of Allowance for US Patent for Novel Topical Lidocaine Formulation for Pain
11. Life Technologies Receives AFNOR Validation for Tests Designed to Detect Listeria Contamination in Food Samples
Post Your Comments:
(Date:10/12/2017)... ... October 12, 2017 , ... ... with the addition of its newest module, US Hemostats & Sealants. , SmartTRAK’s ... hemostats, absorbable hemostats, fibrin sealants, synthetic sealants and biologic sealants used in surgical ...
(Date:10/11/2017)... ... 11, 2017 , ... The CRISPR-Cas9 system has ... and avoiding the use of exogenous expression plasmids. The simplicity of programming this ... gain-of-function studies. , This complement to loss-of-function studies, such as with RNAi ...
(Date:10/11/2017)... INDIANAPOLIS , Oct. 11, 2017  VMS BioMarketing, a ... of a nationwide oncology Clinical Nurse Educator (CNE) network, which ... growing need for communication among health care professionals to enhance ... physicians, nurses, office staff, and other health care professionals to ... for breast cancer. ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today announced that ... SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 ... cross the cell membrane and bind intracellular STAT3 and inhibit its function. Dysregulation ...
Breaking Biology Technology:
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
(Date:3/30/2017)... 30, 2017 Trends, opportunities and forecast in ... by technology (fingerprint, AFIS, iris recognition, facial recognition, hand ... by end use industry (government and law enforcement, commercial ... banking, and others), and by region ( North ... Asia Pacific , and the Rest of ...
(Date:3/24/2017)... The Controller General of Immigration from Maldives Mr. Mohamed Anwar ... prestigious international IAIR Award for the most innovative high security ePassport and ... ... Maldives Immigration Controller General, Mr. Mohamed ... the right) have received the IAIR award for the "Most innovative high ...
Breaking Biology News(10 mins):